Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Philip Dormitzer and Mark Cutler.
Philip Dormitzer
Connection Strength
0.467
Mark Cutler
  1. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 08; 596(7871):273-275.
    View in: PubMed
    Score: 0.059
  2. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 07; 595(7868):572-577.
    View in: PubMed
    Score: 0.059
  3. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021 07 29; 385(5):472-474.
    View in: PubMed
    Score: 0.059
  4. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. NPJ Vaccines. 2021 Mar 25; 6(1):44.
    View in: PubMed
    Score: 0.059
  5. Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021 04 15; 384(15):1466-1468.
    View in: PubMed
    Score: 0.058
  6. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021 04; 27(4):620-621.
    View in: PubMed
    Score: 0.058
  7. Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2021 Feb; 590(7844):E17.
    View in: PubMed
    Score: 0.058
  8. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 10; 586(7830):594-599.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.